Patents Assigned to Temple University
-
Publication number: 20190038770Abstract: The present invention includes methods and compositions for elimination of polyoma viruses, such as John Cunningham Virus (JVC), from host cells, and the treatment of polyoma-virus related diseases, such as progressive multifocal leukoencephalopathy (PML). The compositions include isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a polyoma virus.Type: ApplicationFiled: January 24, 2017Publication date: February 7, 2019Applicants: EXCISION BIOTHERAPEUTICS,INC., Temple University of the Commonwealth System of Higher EducationInventors: Kamel KHALILI, Thomas MALCOLM
-
Publication number: 20190032057Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.Type: ApplicationFiled: January 24, 2017Publication date: January 31, 2019Applicants: EXCISION BIOTHERAPEUTICS, INC., Temple University of the Commonwealth System of Higher EducationInventors: Kamel KHALILI, Thomas Malcolm
-
Patent number: 10188728Abstract: Provided are compositions, methods and kits for treating cancer comprising targeted liposomes comprising a chemotherapy agent and a sensitizer for the chemotherapy agent, and non-targeted liposomes comprising an anti-angiogenic agent. In some embodiments, the targeted liposomes are immunoliposomes. In further embodiments, the immunoliposomes bind to Her-2/neu, and the composition is for treating breast cancer.Type: GrantFiled: October 16, 2013Date of Patent: January 29, 2019Assignee: Temple University—Of The Commonwealth System of Higher EducationInventors: Bin Wang, Mohammad F. Kiani, Yuan Tang
-
Publication number: 20190016821Abstract: An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from Protocadherin FAT1 for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen includes detecting and/or measuring the amount of Protocadherin FAT1 peptide fragments present in the biological sample of a subject.Type: ApplicationFiled: January 5, 2017Publication date: January 17, 2019Applicant: Temple University of the Commonwealth System of Higher EducationInventor: Frank N. CHANG
-
Patent number: 10161925Abstract: Provided is a method of detecting mild neurocognitive disturbance (MNCD) or HIV associated dementia (HAD) in a patient comprising detecting the level of acetyl spermine and/or acetyl spermidine from a cerebrospinal fluid test sample of the patient; and comparing the level of acetyl spermine and/or acetyl spermidine in the test sample to the level of the acetyl spermine and/or acetyl spermidine in a cerebrospinal fluid control sample or to a control value for lack of neurocognitive impairment, MNCD or HAD; wherein an elevated level of acetyl spermine and/or acetyl spermidine in the test sample as compared to the level in the control sample or a control value for lack of neurocognitive impairment, or a level of acetyl spermine and/or acetyl spermidine that is similar to that of a control value for MNCD or HAD, indicates that the patient suffers from MNCD or HAD. Also provided are methods for measuring the progression of an HIV-1-associated neurocognitive disorder, as well as methods for staging such a disorder.Type: GrantFiled: March 24, 2015Date of Patent: December 25, 2018Assignees: Temple University—Of The Commonwealth System of Higher Education, The Johns Hopkins UniversityInventors: Salim Merali, Carlos A. Barrerro, Kamel Khalili, Jay Rappaport, Norman J. Haughey, Ned Sacktor
-
Patent number: 10143669Abstract: The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions.Type: GrantFiled: February 23, 2018Date of Patent: December 4, 2018Assignee: Temple University—Of The Commonwealth System of Higher EducationInventor: Mark A. Feitelson
-
Patent number: 10136639Abstract: The present disclosure provides an antimicrobial composition including a polycationic amphiphile compound, and the method of making and the method of using such a compound or composition. The compound having the formula (I) or (II) R1, R2, R3, R4, R5, R6, R10, or R11 is H or a C1-12 alkyl unsubstituted or optionally substituted with a functional group such as —OH, —OR?, —NH2, —NHR?, —NR?2, —N—C(O)R?, —N—C(O)CR??CR?, —SH, —SR?, —O—C(O)R?, —C(O)R?, —CF3, —OCF3, halogen, benzyl, o-vinylbenzyl, m-vinylbenzyl, p-vinylbenzyl, phenyl, allyl, and substituted allyl. R7, R8 or R9 is a C1-12 alkyl unsubstituted or optionally substituted with a functional group such as —OH, —OR?, —NH2, —NHR?, —NR?2, —SH, —SR?, —O—C(O)R?, —C(O)R?, —CF3, and —OCF3. R? is H or a C1-4 alkyl. X or Y is a halogen, m and n are integers in the range from 1 to 25.Type: GrantFiled: November 5, 2014Date of Patent: November 27, 2018Assignees: Villanova University, Temple University of the Commonwealth System of Higher EducationInventors: William Wuest, Kevin Patrick Minbiole
-
Patent number: 10131637Abstract: Disclosed are compounds of the class of 2-phenylacetamides that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.Type: GrantFiled: March 11, 2014Date of Patent: November 20, 2018Assignees: Shifa Biomedical Corporation, Temple University—Of The Commonwealth System of Higher EducationInventors: Sherin Salaheldin Abdel-Meguid, Magid Abou-Gharbia, Benjamin Blass, Wayne Childers, Nabil Elshourbagy, Victor Ghidu, Rogelio Martinez, Harold Meyers, Shaker A. Mousa
-
Patent number: 10123814Abstract: An infusion catheter has an elongate flexible shaft including a wall and a lumen extending between a proximal end and a distal end. The catheter also has a sealing member within the shaft lumen including a wall and a lumen. The catheter also has a slidable, retractable elongate central axis member extending through the shaft and sealing member lumens connected to an end cap. The catheter also has a plurality of eluting arms extending radially around the central axis member, including lumens fluidly connected to the shaft lumen and the distal end cap. A method for treating a thrombus is also disclosed.Type: GrantFiled: October 31, 2017Date of Patent: November 13, 2018Assignees: Temple University—Of The Commonwealth System of Higher Education, Pebble Hill Partners, LLCInventors: Riyaz Bashir, Nick A. Green
-
Publication number: 20180303915Abstract: A method of treating a subject at risk for having an HIV-1 virus infection, by administering to the subject a prophylactically effective amount of a composition comprising a CRISPR-associated endonuclease, and two or more different multiplex guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, and eradicating the HIV-1 proviral DNA from the host cell and preventing HIV-1 retroviral infection.Type: ApplicationFiled: March 12, 2018Publication date: October 25, 2018Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Kamel Khalili, Wenhui HU
-
Publication number: 20180296649Abstract: Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to one or more target nucleic acid sequences in a retrovirus genome.Type: ApplicationFiled: June 1, 2016Publication date: October 18, 2018Applicant: Temple University - of the Commonwealth System of Higher EducationInventors: Kamel Khalili, Wenhui Hu, Yonggang Zhang
-
Publication number: 20180236045Abstract: A method of preventing transmission of a retrovirus from a mother to her offspring, by treating the mother's host cells with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of the proviral DNA, and preventing transmission of the proviral DNA to the offspring.Type: ApplicationFiled: February 1, 2018Publication date: August 23, 2018Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Kamel KHALILI, Wenhui HU
-
Publication number: 20180236042Abstract: A method of treating a subject at risk for having a virus infection, by administering to the subject a prophylactically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5?- to 3?-LTRs of the sequence in the virus, and preventing a retroviral infection.Type: ApplicationFiled: January 29, 2018Publication date: August 23, 2018Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Kamel KHALILI, Wenhui HU
-
Publication number: 20180236046Abstract: A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including an isolated nucleic acid encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, an isolated nucleic acid sequence encoding a first guide RNA (gRNA) having a first spacer sequence that is complementary to a first target protospacer sequence in a proviral DNA, and an isolated nucleic acid sequence encoding a second gRNA having a second spacer sequence that is complementary to a second target protospacer sequence in the proviral DNA, wherein said first target protospacer sequence and said second target protospacer sequence are situated in a long terminal repeat (LTR) of the proviral DNA. A pharmaceutical composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus.Type: ApplicationFiled: February 1, 2018Publication date: August 23, 2018Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Kamel KHALILI, Wenhui HU
-
Publication number: 20180236043Abstract: A method of treating a subject having or at risk for having a virus infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5?- to 3?-LTRs of the sequence in the virus. A method of treating a subject having or at risk for having a virus infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5?- to 3?-LTRs of the sequence in the virus, and causing neither genotoxicity nor off-target editing to the host.Type: ApplicationFiled: January 29, 2018Publication date: August 23, 2018Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Kamel KHALILI, Wenhui HU
-
Publication number: 20180236044Abstract: A personalized method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus, by determining a nucleic acid sequence of the proviral DNA harbored by a subject, designing two or more different guide RNAs (gRNAs) complementary to the proviral DNA sequences in the subject, treating the subject's host cells with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of the proviral DNA, and inactivating the proviral DNA.Type: ApplicationFiled: February 1, 2018Publication date: August 23, 2018Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Kamel KHALILI, Wenhui Hu
-
Publication number: 20180236041Abstract: A method of treating a subject having or at risk for having a virus infection, by administering a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs that are complementary to two target sequences spanning from the 5?- to 3?-LTRs of the sequence in the virus, and completely excising a fragment of greater than 9000-bp of integrated proviral DNA that spanned from its 5?- to 3?-LTRs. A method of treating a subject having or at risk for having a genetic caused disease, by administering a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs that are complementary to two target sequences spanning from the sequence of the subjects DNA greater than 9000-bp that is chromosomally integrated and causes the genetic caused disease, and excising the chromosomally integrated sequence.Type: ApplicationFiled: January 29, 2018Publication date: August 23, 2018Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Kamel KHALILI, Wenhui HU
-
Publication number: 20180228876Abstract: A method of preventing transmission of a retrovirus from a mother to her offspring, by administering to the mother a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and the two or more different multiplex gRNAs, wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and preventing transmission of the proviral DNA to the offspring.Type: ApplicationFiled: April 11, 2018Publication date: August 16, 2018Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Kamel Khalili, Wenhui Hu
-
Publication number: 20180228875Abstract: A personalized method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus, by determining a nucleic acid sequence of the HIV-1 proviral DNA harbored by a subject, designing two or more different multiplex guide RNAs (gRNAs) complementary to the HIV-1 proviral DNA sequences in the subject, administering to the subject a therapeutically effective amount of a composition comprising a CRISPR-associated endonuclease, and the two or more different multiplex gRNAs, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, and eradicating the HIV-1 proviral DNA from the host cell.Type: ApplicationFiled: April 11, 2018Publication date: August 16, 2018Applicant: Temple University of the Commonwea lth System of Higher EducationInventors: Kamel Khalili, Wenhui HU
-
Publication number: 20180228874Abstract: A pharmaceutical composition for use in inactivating an HIV-1 proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different multiplex guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of the HIV-1 proviral DNA, whereby treating the host cell with the composition cleaves a double strand of the HIV-1 proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease and cleaves a double strand of the HIV-1 proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease and thereby excises an entire HIV-1 proviral genome and eradicates the HIV-1 proviral DNA from the host cell, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: February 26, 2018Publication date: August 16, 2018Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Kamel KHALILI, Wenhui HU